神经刺激器引导下舌咽神经注射阿霉素治疗舌咽神经痛的疗效

Effects of glossopharyngeal nerve injection with adriamycin guided by nerve stimulator in the treatment of patients with glossopharyngeal neuralgia

目的评价神经刺激器引导下舌咽神经注射阿霉素治疗舌咽神经痛的安全性及疗效。方法收集2012年1月至2018年3月苏北人民医院疼痛科诊治的舌咽神经痛患者21例,男6例,女15例,年龄47~78岁。采用神经刺激器引导,经颌下入路行舌咽神经阻滞,注射药物为1%阿霉素0.3 ml及复方倍他米松0.5 ml(含二丙酸倍他米松2.5 mg与倍他米松磷酸钠1 mg)。观察治疗前及治疗后1周、1个月、3个月、6个月及1年时视觉模拟评分(VAS),并观察疗效及并发症。结果本组21例患者,在治疗前及治疗后1周、1个月、3个月、6个月及1年时VAS评分分别为(7.87±0.60)、(3.76±0.42)、(3.12±0.28)、(2.98±0.33)、(2.57±0.50)、(1.65±0.36),差异有统计学意义(F=102.05,P<0.05);治疗效果在1个月后趋于稳定;总有效率为90.5%(20/21例),未见明显并发症。结论神经刺激器引导下舌咽神经注射阿霉素治疗舌咽神经痛安全、有效。

Objective To explore the safety and effects of adriamycin injection in glossopharyngeal nerve guided by nerve stimulator in the treatment of patients with glossopharyngeal neuralgia.Methods Twenty-one patients with glossopharyngeal neuralgia,6 males and 15 females,aged 47-78 years old,from January 2012 to March 2018 in the department of Pain Medicine of Northern Jiangsu People's Hospital,were treated by nerve block with adriamycin in glossopharyngeal nerve guided by nerve stimulator.The injected drugs included 1%adriamycin 0.3 ml and compound betamethasone 0.5 ml(containing betamethasone dipropionate 2.5 mg and betamethasone sodium phosphate 1 mg).Visual analogue scale(VAS)was recorded before the treatment and 1 week,1 month,3 months,6 months and 1 year after the treatment.The effects and the complications were observed after the treatment.Results VAS was(7.87±0.60),(3.76±0.42),(3.12±0.28),(2.98±0.33),(2.57±0.50)and(1.65±0.36)respectively before the treatment,and 1 week,1 month,3 months,6 months,1 year after the treatment in the 21 patients.The difference was statistically significant(F=102.45,P<0.05).The therapeutic effect tended to stabilize at one month after the treatment.The total effective rate was 90.5%(20/21 cases).No complications were observed in all patients.Conclusion Adriamycin injection in glossopharyngeal nerve guided by nerve stimulator is a safe and effective method for the treatment of patients with glossopharyngeal neuralgia.